Q9ZLT1 AF NFT

Cytotoxicity-associated immunodominant antigen

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeifvryx5sizkknqkdsgrdvx6relbmplnsujx5kwuibor6oecr5km4y/metadata.json
IPFS of structure file: 
bafybeibuu3zxgpkec2pmbssg763anhoabnb2vwtamq6ukjjjowzlofk36i/AF-Q9ZLT1-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x84e61bE2B32b5580a50fE9Dd16c41b59E17F5FB5
First NFT owner address (bech32): 
genesis1snnphc4n9d2cpfg0a8w3d3qmt8sh7ha4mp9dgt
Current NFT ID #49292 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
49292
Accession (UniProt):
Q9ZLT1
Name::
Cytotoxicity-associated immunodominant antigen
Experimental Method:
Predicted structure
Sequence source:
HELICOBACTER PYLORI (STRAIN J99 / ATCC 700824)

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q9ZLT1 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q9ZLT1|CAGA_HELPJ Cytotoxicity-associated immunodominant antigen OS=Helicobacter pylori (strain J99 / ATCC 700824) OX=85963 GN=cagA PE=4 SV=1 MTNEAINQQPQTEAAFNPQQFINNLQVAFIKVDNVVASFDPNQKPIVDKNDRDNRQAFEKISQLREEFANKAIKNPTKKNQYFSSFISKSNDLIDKDNLIDTGSSIKSFQKFGTQRYQIFMNWVSHQNDPSKINTQKIRGFMENIIQPPISDDKEKAEFLRSAKQAFAGIIIGNQIRSDQKFMGVFDESLKERQEAEKNGEPNGDPTGGDWLDIFLSFVFNKKQSSDLKETLNQEPVPHVQPDVATTTTDIQSLPPEARDLLDERGNFSKFTLGDMNMLDVEGVADIDPNYKFNQLLIHNNALSSVLMGSHNGIEPEKVSLLYGNNGGPEARHDWNATVGYKNQRGDNVATLINVHMKNGSGLVIAGGEKGINNPSFYLYKEDQLTGSQRALSQEEIQNKVDFMEFLAQNNAKLDNLSKKEKEKFQNEIEDFQKDSKAYLDALGNDHIAFVSKKDKKHLALVAEFGNGELSYTLKDYGKKADKALDREAKTTLQGSLKHDGVMFVDYSNFKYTNASKSPDKGVGATNGVSHLEAGFSKVAVFNLPNLNNLAITSVVRQDLEDKLIAKGLSPQEANKLVKDFLSSNKELVGKALNFNKAVAEAKNTGNYDEVKQAQKDLEKSLKKRERLEKDVAKNLESKSGNKNKMEAKSQANSQKDEIFALINKEANRDARAIAYAQNLKGIKRELSDKLENINKDLKDFSKSFDEFKNGKNKDFSKAEETLKALKGSVKDLGINPEWISKVENLNAALNEFKNGKNKDFSKVTQAKSDLENSIKDVIINQKITDKVDNLNQAVSVAKATGDFSGVEQALADLKNFSKEQLAQQAQKNEDFNTGKNSALYQSVKNGVNGTLVGNGLSKAEATTLSKNFSDIKKELNAKLGNFNNNNNNGLENSTEPIYTQVAKKVKAKIDRLDQIASGLGDVGQAASFLLKRHDKVDDLSKVGLSANHEPIYATIDDLGGPFPLKRHDKVDDLSKVGLSREQKLTQKIDNLNQAVSEAKASHFDNLDQMIDKLKDSTKKNVVNLYVESAKKVPTSLSAKLDNYATNSHTRINSNVKNGTINEKATGMLTQKNSEWLKLVNDKIVAHNVGSAPLSAYDKIGFNQKNMKDYSDSFKFSTRLSNAVKDIKSGFVQFLTNIFSMGSYSLMKASVEHGVKNTNTKGGFQKS